Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arch Biopartners Inc (OP: ACHFF )

0.9935 USD UNCHANGED
Streaming Delayed Price Updated: 3:56 PM EST, Feb 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.9935
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.9935
Today's Range 0.9935 - 0.9935
52wk Range 0.5250 - 1.320
Shares Outstanding 58,457,929
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide
From GlobeNewswire News Releases
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
From GlobeNewswire News Releases

Performance

YTD
-12.85%
-12.85%
1 Month
-3.07%
-3.07%
3 Month
-12.08%
-12.08%
6 Month
-1.63%
-1.63%
1 Year
+61.54%
+61.54%

More News

Read More
Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19
From GlobeNewswire News Releases
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
From GlobeNewswire News Releases
Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19
From GlobeNewswire News Releases
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
From GlobeNewswire News Releases
Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida
From GlobeNewswire News Releases
Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients
From GlobeNewswire News Releases
Arch Biopartners Obtains DTC Eligibility for its Common Shares on OTCQB
From GlobeNewswire News Releases
Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST
From GlobeNewswire News Releases
Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.